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Background: The burning mouth syndrome (BMS) presents with symptoms of burning or pain in the oral cavity, 
especia lly in the tongue, lips, and hard and soft palates.  Its etiology is yet to be elu cidated, but it is considered to 
be affected by multifactorial, psychological, and local and systemic factors. 
Objective: Evaluate the effect of LLLT in the treatment of BMS.
Material and Methods: Twenty-one BMS patients were randomly assigned to two groups: 12 in the laser group 
(LG) and 9 in the control group (CG). Patients in the LG underwent 2-week sessions of LLLT for 4 weeks. The spot 
tip area of this tool is 0.088cm2, semi-conductor GaAlAs, with a wavelength of 808nm ±5nm (infrared), 200 mW 
output power, 1.97W/cm2 of power density, 3 J energy per point and application time 15 seconds per point. LLLT 
was applied punctually, in continuous emissions, on each of the sites where there was a symptom. Symptoms were 
evaluated with a visual analogue scale (VAS) and patient psychological profiles were assessed using the Hospital 
Anxiety-Depression Scale. No side effects were recorded. Statistical analysis was carried out via ANOVA and 
logistic regression analysis. 
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Introduction
Burning mouth syndrome (BMS) is a common patholo-
gy. It is characterized by a stinging sensation or someti-
mes even pain, both of which in the absence of associa-
ted pathology or lesions (1). Those who suffer from BMS 
have symptoms of varying degrees and the intensity can 
be attributed to their general clinical status, especially 
with respect to psychological factors (2-4), which may 
also be linked to the sleep disorders of some patients 
(5). The lack of unified criteria makes the diagnosis of 
BMS difficult and causes variation in epidemiological 
data, depending on the researcher who is analyzing such 
data (1,6,7). Almost all of the literature mentions a clear 
predominance in women, and the average age of those 
affected is between 50 and 60 years old, although it can 
appear at younger ages (7-9). BMS is clinically manifes-
ted with a stinging, burning, and painful sensation that 
is mostly continuous throughout the day. This sensation 
is chronic and it is observed at different localizations 
within the oral cavity, without the presence of any le-
sion that could justify such symptoms, or any clinical 
or histological changes (1,6,9). Patients describe a fee-
ling of dry mouth and taste alterations, such as a bitter 
or metallic taste (10). The description of the symptoms 
varies for each patient, although the majority of patients 
describe it as chronic and unbearable (9-11). Food that 
is spicy or very hot, drinks, stress and fatigue are all fac-
tors that are most frequently reported by patients to the 
worsen the symptoms (1,2). The discomfort tends to be 
continuous or intermittent and may increase throughout 
the day (9-11). 
BMS has a multifactorial origin. Systemic factors (9,12), 
local factors (9,10,13-15) and psychological factors such 
as stress, anxiety and depression (3,5,13,14,16-18) are 
all possible causes. However on rare occasions BMS can 
be directly linked to an etiopathogenic factor that acts 
either locally or systemically (1). The treatment of BMS 
continues to pose serious problems; it is still not clear 
which etiopathogenic factors are responsible for such 
pathology, thus making it difficult to make therapeutic 
advances. The main objective of treatment is to control 
the multiples factors that are related to BMS, therefore 
decreasing the symptoms that patients report (11).
The therapeutic properties of laser radiation have been 
studied for many years, especially with respect to cer-
Results: The initial VAS score mean was 8.9 for the LG and 8.3 for the CG (p > 0.05). After the eighth session the 
VAS score was 5.5 and 5.8 respectively, and at two months it was 4.7 and 5.1 respectively. Improvement variables 
were established by dichotomizing the pain scales. We obtained levels of significance for the improvement variable 
for the LG at the two-month follow-up (p=0.0038) and for the univariate analysis of the treatment. The improvement 
was marginally significant in the multivariant analysis of: dry mouth, dysgeusia, pain and the treatment (p=0.0538). 
Conclusions: LLLT may be an alternative treatment for the relief of oral burning in patients with BMS.
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tain indications and contraindications. Non-ablative 
laser therapy, also known as clinical laser, or low-level 
laser therapy (LLLT) was developed in 1965 by Sinc-
lair and Knoll. Because of the energy density and the 
wavelength, low-level lasers are used in medicine, due 
to their bio-modulating action and their ability to pene-
trate tissue (19). Different studies have demonstrated the 
analgesic, anti-inflammatory and repairing effect that 
this type of radiation has on tissues, but there is a need 
for more research to strengthen the data from these trials 
and establish the most efficient clinical protocols (20-
23).   
To date it has been verified that low-level laser radiation 
therapy can be effective in decreasing the symptoms of 
patients with BMS (20,21,24-26).  Santos et al. (2011) 
(24), treated 10 patients with BMS with weekly sessions 
of LLLT for a period of 10 weeks, using the InGaAIP 
laser diode in continuous mode.  They used a wavelen-
gth of 660 nm, 40 mW, 20 J/cm2 of dosimetry and 0.8 J 
per point for 10 seconds. The intensity of the symptoms 
was assessed at all of the sessions with a visual analog 
scale (VAS). The patients reported improvement after 
the laser treatment, with a reduction in symptoms of up 
to 50% at the tenth session period. The analgesic effect 
of the laser radiation is due to the inhibition of nocicep-
tive mediators and the release of endogenous analgesic 
substances, such as endorphins, by the Central Nervous 
System (CNS), which works to inhibit the transmission 
of painful stimuli (27,28). As an immediate effect, after 
the application of the laser an elevation in the cell mem-
brane potential occurs, as well as the reduction of the 
speed of nerve impulse conduction (28).  
On the other hand, it is important to stress that low power 
laser therapy is a non-invasive treatment; it is well to-
lerated by patients and effective for acute and chronic 
pain. If we start from the premise that patients with BMS 
should be treated to improve their quality of life, even 
if this implies that they are not completely cured, and 
when considering that the objective of treatment is to 
improve symptoms, given that they are difficult to com-
pletely control, LLLT can be a possible alternative with 
no side effects.
Based on what has been previously mentioned, the 
hypothesis is that the low-power laser can be effec-
tive in controlling the symptoms of the BMS and that 
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its contraindications are minimal. In order to test such 
hypothesis we pose the objective of clinically evaluating 
the effect of low-level laser radiation on the reduction of 
symptoms in patients with BMS, as well as evaluating 
the degree of anxiety of patients before starting the treat-
ment and at the two-month follow-up.
Material and Methods
This is a clinical trial (prospective, randomized, dou-
ble-blind, placebo-controlled). The present study has 
been approved by the Research Ethics Committee at the 
DHUB and by local committees, based on the Declara-
tion of Helsinki. Each of the participants in the study 
signed an informed consent form. The sample compri-
sed 21 patients of both sexes with BMS diagnosis. The 
study population consisted of patients who were treated 
in the postgraduate program of Medicine, Surgery and 
Implantology and Dentistry in Oncology and Immuno-
compromised Patients at the School of Dental Medicine 
of the University of Barcelona. Their clinical activity 
was recorded at the Dental Hospital - University of Bar-
celona (DHUB). 
The study included patients over 40 years old who re-
ported symptoms of burning or pain in the oral mucosa 
of at least 3 months of duration. Patients with uncon-
trolled systemic diseases (ASA III, IV) or without cli-
nical activity of BMS, or a VAS score below 3 out of 
10. Those patients who did not agree to participate in 
the study were also excluded. All the patients received 
instructions regarding oral hygiene, mucosal hydration 
and were advised to avoid spicy and citric foods, as well 
as alcoholic beverages and tobacco.
-Trial Procedures
A general medical history was obtained for all patients, 
as well as a specific medical history with respect to 
BMS (evolution time, level of pain, treatment, etc.). The 
Hospital Anxiety and Depression Scale (HADS) were 
also used at the beginning of the treatment and at the 














Discomfort associated with the technique 
1. Did the use of the device cause you discomfort? YES (  ) NO (  ) 
2. Did you experience any discomfort the day after treatment? YES (  ) NO (  ) 
3. Please specify the discomfort that you experienced: ……………………… 
4. Did you feel uncomfortable during the laser sessions? YES (  ) NO (  ) 
5. If you said YES answering the question number 4: Why?….… 
6. Did the sessions seem to last a long time? YES (  ) NO (  ) 
7. Did the frequency of the sessions (twice a week) seem adequate or was it difficult to attend the 
sessions? YES (  ) NO (  ) 
8. Would you repeat the treatment again? YES (  ) NO (  ) 
9. Would you recommend it? YES (  ) NO (  ) 
10. Rate your overall comfort level with the technique from 1 to 10 (  ) 
(1, very uncomfortable, 10, very comfortable)    
11. Other comments:….………………………………………………………... 
sess the discomfort associated with the laser technique 
(Table 1). Two groups were randomly created: Laser 
Group (LG): n= 12; Control Group (CG): n=9. 
A bi-weekly application of a low-level laser diode (Thor 
Laser®) was performed on the LG for 4 weeks; total 
of 8 sessions. The spot tip area of this tool is 0.088cm2, 
semi-conductor GaAlAs, with a wavelength of 808nm 
±5nm (infrared), 200 mW output power, 1.97W/cm2 of 
power density, 3 J energy per point and application time 
15 seconds per point. LLLT was applied punctually, in 
continuous emissions, on each of the sites where there 
was a symptom. The number of laser application points 
was determined by the areas mentioned by the patients 
(Fig. 1): tip of the tongue: 3 points; lateral border of the 
tongue: 4 points; dorsal surface of the tongue: 10 points; 
buccal mucosa: 8 points; labial mucosa: 5 points, hard 
palate: 8 points, soft palate: 3 points; gingiva or alveolar 
mucosa: 3 points by sextant. The patients were reevalua-
ted two months after the end of the treatment.
We used the same protocol for the control group as we 
did for the experimental group (time and application va-
lues) but the laser was deactivated for the entirety of the 
consultation, checked by means of a power meter prior 
to the applications. Neither the patient nor the researcher 
knew if the laser was activated or not. 
-Statistical Analysis
The variable responses used in the present study, VAS 
and the percentage of symptom improvement, were 
summarized as a mean and standard deviation. All data 
were analyzed with the Shapiro-Wilk W-Test to assess 
the normality. Since the data did not have normal distri-
butions, the Friedman ANOVA followed by the Wilco-
xon Matched Pairs Test were applied to analyze the di-
fference between the groups. Significance was accepted 
at p<0.05 for all tests. The software used was SPSS (Stat 
Software, Inc., Tulsa, OK).
Results 
All the patients in the sample (n=21) completed the 
Table 1: Questionnaire used for patients with BMS to obtain information about the level of discomfort associated with the 
laser technique.
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Fig. 1: Diagram of points to illustrate the application of the low-level laser on the lower labial mu-
cosa membrane and on the dorsal surface of tongue.
study (12 in the LG and 9 in the CG), there were 20 
women (95%) and one male, who participated in the 
control group. The average age was 66.3 (range of 61-
81, SD=6.9), showing no differences between the two 
groups (LG=66.3±7.52 and CG=66.4±6.31; p=6.699). 
The rest of the clinical variables relating to the symp-
toms of burning did not show differences between the 
two groups (Table 2). There was only marginal signifi-
cance with regard to the burning sensation (p= 0.0653) 
(Table 2).  With respect to the evolution time of the 
symptoms, there were no differences between the two 
groups; the average was 59 months for the LG and 56 
months for the CG, with a maximum range of 10.8 years 
and 8 months. 
The average value of the initial VAS was 8.9 for the LG 
and 8.3 for the CG; at the eighth session it was 5.5 and 
5.8 respectively and at the two-month follow-up it was 
4.7 and 5.1 respectively (Fig. 2). All patients were taking 
at least one medication: one patient took four different 
medications, four patients took three different medica-








Age 66,3±7.52 66,4±6.31 66,5±6.99 0,0997
n (%) n (%) n (%)
Tobaco 0 (0%) 1 (11,1%) 1 (4,7%) 0,9999
Dry mouth 9 (75%) 7 (77%) 16 (76%) 0,4008
Dysgeusia 5 (41%) 5 (55%) 10 (47%) 0,1373
Burning 11 (91%) 9 (100%) 19 (90%) 0,9981
Sunburn 11 (91%) 7 (77%) 18 (85%) 0,0653
Pain 1 (8%) 7 (77%) 8 (38%) 0,9975
Table 2: Descriptive variables related to BMS symptoms.
LG: laser group. CG: control group.
It is worth noting that 6 patients (28%) were taking psy-
chotropic medication. With regard to the medical his-
tory, 2 patients had no other relevant medical history, but 
8 patients (38%) suffered from three or more concomi-
tant diseases, 6 of them were cardiovascular diseases, 7 
had high blood pressure and 8 of them were taking anti-
platelet drugs. Ten of the patients (47%) had a comple-
tely normal oral examination. Six showed signs of white 
tongue; one had white tongue, geographic tongue and 
actinic cheilitis, this patient corresponded to the LG, and 
went from a VAS score of 10 to a VAS score of 3 over 
the two-month period.
In reference to the clinical manifestations, 8 patients 
were labeled with Lamey Type I BMS (14), 13 were 
described as having Type II, and none of the patients 
met criteria for Type III. There were no differences be-
tween the control and treatment groups. With respect to 
the localization of the symptoms, 20 of the 21 patients 
were affected on the tongue at various localizations: 13 
on the tip of the tongue, the dorsal surface and the lateral 
borders, 13 on the tip of the tongue and the dorsal surfa-



















1 2 3 4 5 6 7 8 9 10 11 12
LG	Initial	VAS LG	After	treatment	VAS LG	Follow-up	VAS
Fig. 2: Dates of basal VAS, after treatment (8 applications) and follow-up (two months). LG: Laser group; CG: 
Control group.
ce, 2 on the tip of the tongue and the lateral borders, 18 
on just the tip of the tongue, 1 on just the dorsal surface 
and 1 on just the lateral borders. The palate was affec-
ted in 9 patients (43%) and 8 of them coincided with 
some kind of manifestation on the tongue. The lips were 
affected in 11 patients (52%), but in all cases there was 
some kind of concomitant manifestation on the tongue. 
A total of 6 patients had manifestations on areas besides 
the tongue, lip or palate; but in all cases there were con-
comitant manifestations on the tongue, especially on the 
tip of the tongue.  There were no differences between the 
groups and their response, based on the localization of 
the symptoms. All the patients, without any exceptions, 
showed a good level of tolerance to the technique utili-
zed and 19 of them (90%) would repeat treatment again.
In order to dichotomize the pain scales, we established 
improvement variables for each one of the measure-
ments; improvement was considered to have taken place 
when the score decreased 2 points or more as compared 
to the previous measurement. We likewise established 
the improvement variable of 30% at the two-month fo-
llow-up, if the initial VAS score decreased 30%. There 
was a 50% improvement, if the initial value decreased 
50%, and finally the VAS≤5 variable, if this was the re-
sult obtained at the two-month follow-up visit. Based on 
these variables we obtained clear significance for the LG 
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in the improvement variable after the two month period, 
showing p=0.0038 in the univariate analysis related to 
the implemented treatment (Table 3), and proving to be 
marginally significant in the multivariate analysis ca-
rried out with respect to: dry mouth, dysgeusia, pain and 
the implemented treatment (p=0.0538) (Table 4).
In regard to the psychological profiles of the patients, 
there were no statistically significant differences be-
tween the groups before or after the treatment (Table 5).
Discussion
The present study has clinically assessed LLLT effects in 
the treatment of patients with burning mouth syndrome. 
The patients in this study were treated with LLLT after 
VARIABLE Avg SD p Odds 
Ratio
C. I. 95% Inf. 
Limit
C. I. 95% Sup. 
Limit
VAS≤5 0.3810 0.4856 0.6963 1.4286 0.2363 8.6374
VAS 50% 0.2857 0.4518 0.5739 1.7500 0.2422 12.6422
VAS 30% 0.5238 0.4994 0.1268 4.000 0.6395 25.0208
VAS-Improvement 0.6667 0.4714 0.0038 22.00 1.8568 260.6595
Table 3: Descriptive analysis of the variables at the two-month mark: VAS≤5, VAS 50%, VAS 30%, VAS-Improvement. (0 = CG, 
without laser, 1 = LG, with LLLT).
LG: laser group. CG: control group. 
Explanatory variable B P Odds Ratio C. I. 95% Inf. 
Limit
C. I. 95% Sup. 
Limit
Age -0.2290 0.0997 0.7953 0.6055 1.0446
Smoking 1.8462 0.9999 6.3360 0.0000 -
Dry mouth -1.4349 0.4008 0.2381 0.0084 6.7705
Dysgeusia -2.7943 0.1373 0.0612 0.0015 2.4384
Burning -41.1745 0.9981 0.0000 0.0000 -
Sunburn 5.3070 0.0653 201.7423 0.7140 57005.0960
Pain -24.1550 0.9975 0.0000 0.0000 -
Table 4: Multivariate logistic regression analysis of the influence of the independent variables age, smoking (0 = non-smoker, 1 = smoker), 
dry mouth (0 = absent, 1 = present), dysgeusia (0 = absent, 1 = present), burning (0 = absent, 1 = present), on the dependent variable “treatment 
group” (0 = CG, without laser, 1 = LG, with LLLT).
Overall model fit: Chi Square = 15.7921.6; df = 7; p = 0.0271.
GL GP
No symptoms Borderline Disease 
presence






0% 33% 24% 0% 10% 33%





24% 10% 24% 5% 10% 29%
43% 10% 5% 24% 10% 10%
Table 5: Percentage of patients according to scores on the Hospital Anxiety and Depression Scale (HADS). There were no differences between 
the groups before or after the treatment.
LG: laser group; GC: control group.
having tried treatments with other types of medication 
and not having any satisfactory relief of the symptoms 
with such treatment. 
In the series with 10 patients and no control group, publi-
shed by Santos et al. (2011) (24), the use of the low-level 
laser showed a reduction in the average percentage of 
the intensity of the pain of up to 58.2% according to VAS 
scale values at the tenth session. The initial scores from 
the visual analog scale were significantly lower after the 
forth laser application, when compared to those values 
from the first session. Kato et al. (2010) (25) utilized 
the LLLT on the localization where the patients reported 
symptoms for 11 patients with BMS. The affected areas 
were irradiated once a week, in continuous mode, with 
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a wavelength of 790 nm and 6 J/cm2 of dosimetry. The 
intensity of the symptoms was recorded by means of the 
VAS in each one of the three sessions, as well as six 
weeks after the treatment had ended. At the end of the 
study the authors verified that the experimental group 
showed significant symptom improvement as compared 
to their status at the beginning of the treatment. The pa-
tients reported a decrease of 80.4% in the intensity of 
the symptoms after the laser radiation treatment, which 
suggests that LLLT can be an alternative for BMS. 
Spanemberg et al. (2015) (26) aimed to clinically assess 
the effect of different LLLT protocols in the treatment of 
BMS patients and presented three protocols, red and in-
frared, in a randomized, blind, placebo-controlled study, 
seeking positive outcomes for the management of BMS. 
A diode laser was used in 78 BMS patients punctually on 
each of the sites with the symptom.  Patients were ran-
domly assigned into four groups: Infrared weekly (830 
nm, 100 mW, 5 J, 176  J/cm2 176  J/cm2, 50 s, LLLT wee-
kly sessions, 10 sessions); Infrared three times a week 
(830 nm, 100 mW, 5 J, 176  J/cm2 176  J/cm2, 50 s, three 
LLLT weekly sessions, 9 sessions); Red laser (685 nm, 
35 mW, 2 J, 72  J/cm2 72  J/cm2, 58 s, three LLLT weekly 
sessions, 9 sessions); and control-group. There was sig-
nificant reduction of the symptoms in all groups at the 
end of the treatment (P<0.001), which was maintained 
in the follow-up (P<.0001). The results shows that the 
protocols used infrared laser were very effective in redu-
cing BMS symptoms. 
However, authors like Vukoja et al. (27) were incapable 
of confirming such results and they suggest that the thera-
peutic benefit of the laser in patients with BMS is caused 
by the placebo effect, and its duration is limited over time. 
Many BMS patients mention decrease in symptoms and 
psychological improvement due to the fact that they have 
been receiving medical attention and advice. Throughout 
the literature we find few placebo-controlled clinical trials 
that utilize the low-level laser in patients with BMS. The 
results were satisfactory in the study that we have presen-
ted, and the fact that it was a double-blind study allows us 
to minimize the interference of the placebo in the results 
as much as possible. 
Studies have shown that BMS can have neuropathic 
origin (10,12,16).  López-Jornet et al. (10) suggest that 
hyperactivity of trigeminal nociceptive pathways can 
produce an intense response to the action of irritating 
factors, leading to the occurrence of BMS symptoms. 
The relief of symptoms of a burning sensation provided 
by the laser therapy is probably caused by nocicepti-
ve modulation due to the liberation of endorphins and 
enkephalins (28-31). In addition to this, the laser dio-
de can reduce inflammation by means of increasing the 
production of PG-I2 (31) and PG-E2 (32), thus increa-
sing the formation of blood vessels (31). In this study, 
the majority of the patients experienced burning on the 
tongue, in addition to other localizations, and although 
the LLLT was topically administered, the laser is also 
capable of increasing the blood flow when it is applied 
directly to the affected areas (33).  
López-Jornet et al. (34) investigated the quality of life of 
216 patients with oral mucosa diseases. The lowest sco-
res were found in patients with burning mouth syndro-
me. Ni Riordain et al. (35) observed that after treatment, 
patients with BMS exhibited improvement in quality of 
life, thus demonstrating that the disorder has a negative 
impact on physical, mental and social well-being. Souza 
et al. (36) described the impact of BMS on health-related 
quality of life in patients with this disease. When evalua-
ting the psychological profile of the patients, although 
we did not find statistically significant differences, the 
HADS scores showed that anxiety decreased after the 
low-level laser treatment. A possible explanation for this 
could be the decrease, although slight in some cases, in 
the symptoms of burning and pain experienced by pa-
tients before beginning the laser treatment. Femiano et 
al. in 2004 (18) stated that the increase in BMS pain is 
associated with the frustration of being affected by the 
disease and/or the patients’ dependence on others when 
they are faced with problems that are not resolved. This 
thus supports the evidence that psychological stress can 
be a significant factor in the development of BMS, at 
least in some cases.
Different researchers have evaluated the possible adver-
se effects of LLLT, but no significant results were found 
(26,28,37). Our study coincides with these data. All of the 
patients had a satisfactory response to the treatment. There 
were no relevant side effects and the majority of patients 
completed the treatment without interruption. Only one pa-
tient abandoned the study due to discomfort experienced 
with the technique, this patient was in the laser group. All 
of the other individuals showed a good level of tolerance 
throughout the study and would repeat the treatment. 
The parameters used in our study aimed at the analgesic 
effect, once neuropathic factors have been suggested as 
the cause of BMS. Due to the variability of options re-
garding LLLT parameters, we believe that several proto-
cols, besides the one applied in the present study, could 
bring beneficial results to the BMS patients.
Based on the results of this study we can conclude that 
for a small number of patients with BMS the results 
of the low-level laser treatment were satisfactory. This 
treatment could be an acceptable alternative to psy-
choactive drugs. We believe that studies with a long 
follow-up period, as well as those with a large number 
of participants are fundamental to confirm the effective-
ness of this therapeutic alternative.
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